Outcomes with fewer IC + Ven consolidation cycles in ND AML

Results from a retrospective analysis, evaluating the impact of fewer first-line intensive chemotherapy (IC) + venetoclax (Ven) consolidation cycles on overall survival (OS) and relapse-free survival (RFS) in patients with newly diagnosed (ND) acute myeloid leukemia (AML), were published in the American Journal of Hematology by Marvin-Peek et al. Patients in Cohort 1 (n = 49) stopped first-line treatment for reasons other than proceeding to allogeneic hematopoietic stem cell transplantation (allo-HSCT) and patients in Cohort 2 (n = 83) stopped first-line treatment for allo-HSCT. Each cohort was separated into patients who received either ≤1 or ≥2 consolidation cycles of IC + Ven.

Key data: The median OS and RFS were not reached in either cohort. At a median follow-up of 33.5 months in Cohort 1, no significant differences in 2‑year OS (69% vs 67%; p = 0.93) or 2‑year RFS (63% vs 58%; p = 0.95) were observed between patients who received ≤1 vs ≥2 IC + Ven consolidation cycles. In Cohort 2, at a median follow-up of 36.0 months, there was no difference in 2‑year OS (79% vs 85%; p = 0.81) or 2‑year RFS (78% vs 81%; p = 0.98) between patients receiving ≤1 or ≥2 consolidation cycles of IC + Ven. There was no significant difference in cumulative incidence of relapse (CIR) between groups in Cohort 1 (p = 0.69) or Cohort 2 (p = 0.60).

Key learning: Results indicate that fewer IC + Ven consolidation cycles do not adversely affect survival outcomes in patients with ND AML. Given the potential cumulative toxicity of IC + Ven, these findings support treating this population with fewer consolidation cycles.